| h-3d993b5d | Metabolic Circuit Breaker via Lipid Droplet Modulation | 0.71 | 0.60 | PLIN2 | debated | 2026-04-02 | sda-2026-04-01-gap-009 |
| h-5e68b4ad | Autophagosome Maturation Checkpoint Control | 0.71 | 0.73 | STX17 | debated | 2026-04-02 | sda-2026-04-01-gap-011 |
| h-82922df8 | Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition | 0.71 | 0.65 | LOX/LOXL1-4 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-immunity-c64967ab | TREM2-APOE4 Axis Drives Metabolic Inflexibility in DAM | 0.71 | 0.72 | TREM2, APOE4, LDHA | open | 2026-04-24 | |
| h-var-bed9f3b7ed | TREM2-Mediated Astrocyte-Microglia Cross-Talk in Neurodegeneration | 0.71 | 0.80 | TREM2 | superseded | 2026-04-12 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-9d29bfe5 | Membrane Cholesterol Gradient Modulators | 0.71 | 0.85 | ABCA1/LDLR/SREBF2 | promoted | 2026-04-02 | SDA-2026-04-01-gap-lipid-rafts-2026-04-01 |
| h-8597755b | Orexin-Microglia Modulation Therapy | 0.71 | 0.50 | HCRTR2 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-18cf98ca |
| h-1b47a73770 | APOE4-driven lysosome-to-ER cholesterol transport failure reduces ER-accessible | 0.71 | 0.79 | NPC1 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-f4c8357045 |
| h-587ea473 | Creatine Kinase System Capacity as Neural Energy Reserve Biomarker | 0.71 | 0.50 | CKB | proposed | 2026-04-17 | SDA-2026-04-04-gap-debate-20260403-222618-c698b06a |
| h-d7121bcc | TET2-Mediated Demethylation Rejuvenation Therapy | 0.71 | 0.68 | TET2 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-bc5f270e |
| h-b3d6ecc2 | Lysosomal Enzyme Trafficking Correction | 0.71 | 0.65 | IGF2R | debated | 2026-04-02 | sda-2026-04-01-gap-011 |
| h-var-18aae53fe9 | TREM2-ASM Crosstalk in Microglial Lysosomal Senescence | 0.71 | 0.78 | SMPD1 | promoted | 2026-04-12 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-fb56c8a0 | Endothelial Glycocalyx Regeneration via Syndecan-1 Upregulation | 0.71 | 0.70 | SDC1 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-ee5a5023 |
| h-SDA-2026-04-26-gap | CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of Astrocyte Glymphatic | 0.71 | 0.50 | AQP4 | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260426-001521 |
| h-SDA-2026-04-26-gap | Plasma Claudin-5 Proteolytic Fragments Distinguish Paracellular BBB Breakdown fr | 0.71 | 0.41 | CLDN5 | proposed | 2026-04-26 | SDA-2026-04-26-gap-20260426-002803 |
| h-SDA-2026-04-26-gap | Soluble PDGFRβ as a Peripheral Indicator of Pericyte-Mediated Blood-Brain Barrie | 0.71 | 0.43 | PDGFRB (Platelet-Derived Growth Factor Receptor Beta) | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260426-011448-7c85f5dc |
| h-5cbf67bf98 | Spatiotemporal coupling between TRPML1-mediated lysosomal calcium release and ca | 0.70 | 0.65 | TRPML1/MCOLN1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062150-387cb0ba |
| hyp_test_0a572efb | Test: TREM2 enhances amyloid clearance | 0.70 | 0.40 | TREM2 | archived | 2026-04-04 | test-hypothesis-fixtures-v1 |
| h-2c776894 | Ferroptosis Inhibition for α-Synuclein Neuroprotection | 0.70 | 0.75 | GPX4 | promoted | 2026-04-04 | SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402 |
| h-470ff83e | Microglial Efferocytosis Enhancement via GPR32 Superagonists | 0.70 | 0.50 | CMKLR1 | debated | 2026-04-02 | sda-2026-04-01-gap-014 |
| h-17a2da3f | Astrocyte-Neuron Metabolic Coupling Titration | 0.70 | 0.50 | BDH1 | proposed | 2026-04-17 | SDA-2026-04-03-gap-debate-20260403-222618-2709aad9 |
| h-183fff58 | TDP-43 Pathology Disrupts the HGS-PYGB Autophagy Receptor Cascade in Motor Neuro | 0.70 | 0.72 | TARDBP (TDP-43), HGS, PYGB | proposed | 2026-04-26 | SDA-2026-04-07-gap-pubmed-20260406-062212-ca78691c |
| h-21d25124 | TLR4/MyD88/NF-κB Axis Blockade to Interrupt LPS-Mediated Gut-Brain Neuroinflamma | 0.70 | 0.68 | TLR4, MyD88 (MYD88), NF-κB (NFKB1) | promoted | 2026-04-17 | SDA-2026-04-16-gap-20260416-121711 |
| h-f99ce4ca | Purinergic P2Y12 Inverse Agonist Therapy | 0.70 | 0.65 | P2RY12 | debated | 2026-04-02 | sda-2026-04-01-gap-v2-691b42f1 |
| h-ab41908b | Aryl Hydrocarbon Receptor (AHR) Activation in B Cells Determines AQP4 Tolerance | 0.70 | 0.55 | AHR, IL10, TNFRSF13B, TIGIT, FOXP3 | promoted | 2026-04-14 | SDA-2026-04-13-gap-pubmed-20260410-142329-c1db787b |
| h-0e614ae4 | Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration | 0.70 | 0.70 | SIRT3 | debated | 2026-04-02 | SDA-2026-04-04-gap-epigenetic-reprog-b685190e |
| h-03e31e80 | DAMP-Scavenging Microglial Reset | 0.70 | 0.66 | HMGB1, S100 proteins | proposed | 2026-04-04 | SDA-2026-04-04-gap-neuroinflammation-microglial-20260404 |
| h-5daecb6e | Microglial Purinergic Reprogramming | 0.70 | 0.58 | P2RY12 | debated | 2026-04-02 | sda-2026-04-01-gap-005 |
| h-3d545f4e | Targeted Butyrate Supplementation for Microglial Phenotype Modulation | 0.70 | 0.70 | GPR109A | promoted | 2026-04-03 | SDA-2026-04-01-gap-20260401-225149 |
| h-92cfd75109 | NRF2-Mediated Proteostatic Convergence: Shared Oxidative Stress Response Failure | 0.70 | 0.75 | NFE2L2,KEAP1,HMOX1,SQSTM1,PSMB5 | proposed | 2026-04-28 | |
| h-2fe683915d | Lysosomal Acidification Failure: Convergent GBA1/LAMP2A–mediated Autophagy Dysfu | 0.70 | 0.77 | GBA1,LAMP2A,SCARB2,CTSB,CTSD,TFEB | proposed | 2026-04-28 | |
| hyp-lyso-snca-cf55ff | VPS35 Retromer Dysfunction Creates a GCase Trafficking Bottleneck that Synergize | 0.70 | 0.75 | VPS35 | active | 2026-04-28 | |
| hyp-lyso-snca-357729 | Glucosylceramide Accumulation from GCase Deficiency Disrupts SNX5-Mediated Retro | 0.70 | 0.78 | GBA1 | active | 2026-04-28 | |
| 9a0b729f-5882-442b-8 | Test hypothesis 0 | 0.70 | 0.43 | | proposed | 2026-04-27 | |
| ab0857a9-de30-44f8-9 | Test hypothesis 0 | 0.70 | 0.43 | | proposed | 2026-04-27 | |
| aa3eca6b-10a6-4d1e-8 | Test hypothesis 0 | 0.70 | 0.43 | | proposed | 2026-04-27 | |
| c19ee425-4805-41a9-9 | Test hypothesis 0 | 0.70 | 0.43 | | proposed | 2026-04-27 | |
| h-d8e13922ed22 | MAP6-CRMPS cooperative phosphorylation by GSK3β | 0.70 | 0.70 | MAP6/CRMP2 | proposed | 2026-04-26 | paper-34025352 |
| h-f05d11119f | Pericyte-targeted senolysis or senomorphic therapy will benefit only an early bi | 0.70 | 0.64 | PDGFRB, CDKN2A, CDKN1A, BCL2, BCL2L1 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-de5dfc4391 |
| h-6aebb76ee3 | SCFA-Producing Bacterial Depletion → Loss of Neuroprotective Microenvironment | 0.70 | 0.74 | HDAC3, GPR41 (FFAR3), GPR43 (FFAR2), Nrf2, HMOX1 | proposed | 2026-04-22 | sda-2026-04-01-gap-20260401-225155 |
| h-aa1f5de5cd | TREM2 haploinsufficiency dysregulates microglial synaptic surveillance, switchin | 0.70 | 0.22 | TREM2, TYROBP (DAP12), APOE | proposed | 2026-04-22 | SDA-2026-04-02-gap-synaptic-pruning-microglia |
| h-2c8ecd5282 | AAV-Mediated APOE2/APOE3 Gene Delivery to Convert APOE Genotype | 0.70 | 0.78 | APOE | proposed | 2026-04-22 | SDA-2026-04-02-gap-apoe4-targeting |
| h-50d1ee2566 | Ataxin-2 Polyglutamine Expansions Hijack G3BP1 to Form Toxic, Irreversible Stres | 0.70 | 0.68 | ATXN2 | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041428-e14e6524 |
| h-2850184c77 | NAD+ Decline and SIRT1 Deficiency Drive Epigenetic Reprogramming Toward Senescen | 0.70 | 0.70 | SIRT1/NAMPT/PPARGC1A | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-041439-5f43216e |
| h-4e0d44f33e | TRIM21 as a 'Phase Separation Thermostat' via Catalytic Reversibility | 0.70 | 0.72 | TRIM21 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041423-2d1db50c |
| h-22d6b643b8 | Metabolic Coupling Disruption Sensitizes Motor Neuron mPTP Threshold | 0.70 | 0.72 | PDH (pyruvate dehydrogenase), MCT1/2, PDK, mPTP (ANT/VDAC/Cy | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046 |
| h-49722750cf | m6A RNA Modification as Address Code for Granule Targeting | 0.70 | 0.72 | METTL3, METTL14, FTO, ALKBH5, YTHDF1, YTHDF2, YTHDC1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041428-53b81741 |
| h-53fd55dc89 | FOXO3-Pioneer Factor Complex Stabilizes Heterochromatin Under Oxidative Stress | 0.70 | 0.70 | FOXO3; SIRT1 | proposed | 2026-04-21 | SDA-2026-04-10-gap-20260410-091440 |
| h-58e4635a | SASP-Mediated Complement Cascade Amplification | 0.70 | 0.70 | C1Q/C3 | promoted | 2026-04-02 | sda-2026-04-01-gap-013 |
| h-db6aa4b1 | Mechanosensitive Ion Channel Reprogramming | 0.70 | 0.55 | PIEZO1 and KCNK2 | debated | 2026-04-02 | sda-2026-04-01-gap-007 |